Initiate a Phase 3 trial of AXS-12 in narcolepsy
Delivered after the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 1 Mar 2021
- Due
- 30 Jun 2021
- Delivered
- Q3 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Axsome is planning to initiate a Phase 3 trial of AXS-12 in the treatment of narcolepsy in the second quarter.”
What we found
Evidence strength A What the grades mean
The Phase 3 AXS-12 narcolepsy trial was initiated in the third quarter of 2021, after the second-quarter 2021 deadline; an August 2021 filing had already moved the timing to Q3.
-
A Axsome Therapeutics, Inc. 10-Q filed 2021-11-08
“A randomized, placebo-controlled Phase 3 trial with AXS-12 in narcolepsy was initiated in the third quarter of 2021” ✓ confirmed on the page
-
A Axsome Therapeutics, Inc. 8-K filed 2021-08-09
“we remain on track to initiate the planned Phase 3 trial of AXS-12 for the treatment of narcolepsy this quarter.” ✓ confirmed on the page
-
A Axsome Therapeutics, Inc. 8-K filed 2021-08-09
“Axsome is on track to initiate a Phase 3 trial of AXS-12 in the treatment of narcolepsy in the third quarter.” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Phase 3 trial of AXS-12 for narcolepsy
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Axsome Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-AXSM-024907 · Corrections policy